ReviewEuropean child & adolescent psychiatry2026
Neurodevelopmental outcomes following prenatal cannabinoid exposure: a systematic review.
Review in European child & adolescent psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabis use during pregnancy is increasing worldwide, yet evidence regarding its long-term neurodevelopmental consequences remains heterogeneous and inconclusive. This systematic review aimed to synthesise observational evidence on the association between prenatal cannabis exposure and neurodevelopmental outcomes from birth to adolescence. A systematic search of PubMed/MEDLINE, Web of Science, and PsycINFO was conducted from database inception to October 2025. Observational studies evaluating neurodevelopmental outcomes following prenatal cannabis exposure were included. Outcomes were grouped by domain and age group. Risk of bias was assessed using the Newcastle-Ottawa Scale. Due to substantial heterogeneity in exposure definitions, outcome measures, and confounder adjustment, findings were synthesised narratively. Seventy-two studies met inclusion criteria. Associations appeared to be domain-specific rather than reflecting global neurodevelopmental impairment. Behavioural dysregulation, attention-related difficulties, and executive functioning showed the most consistent associations with prenatal cannabis exposure, with 73%, 69%, and 70% of studies within these domains reporting negative associations, respectively. In contrast, most studies found no significant associations with global cognition (84%), language (92%), or motor development (60%) after adjustment for confounders. Several cohorts suggested stronger associations with heavier or persistent cannabis exposure after maternal awareness of pregnancy, indicating possible dose-response and timing effects. Current evidence does not consistently support global neurodevelopmental impairment following prenatal cannabis exposure but suggests a pattern of selective vulnerability in behavioural, attention and executive regulatory domains. Together, these findings support cautious clinical counselling and highlight the need for high-quality longitudinal studies with improved exposure and outcome measurements, and rigorous confounder control.
Indexed as
Identifiers
42400661What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.